CompletedPHASE1, PHASE2NCT00529360

Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL

Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
New York Medical College
Principal Investigator
Mitchell S Cairo, MD
New York Medical College
Intervention
Clofarabine(drug)
Enrollment
32 enrolled
Eligibility
30 years · All sexes
Timeline
20072016

Study locations (1)

Collaborators

Genzyme, a Sanofi Company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00529360 on ClinicalTrials.gov

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

← Back to all trials